A Trial of Guanfacine-er for Cannabis Use Disorder

Status Active, not recruiting

Clinical Trial Summary

The primary purpose of this study is to investigate the effect of guanfacine-ER on reductions in cannabis use and explore its effects on impulsivity and withdrawal through a hybrid in-person and virtual trial of treatment-seeking individuals with Cannabis Use Disorder (CUD), and assessing the feasibility of the virtual components of the study.

Clinical Trial Description

This will be a 12-week randomized, double-blind, placebo-controlled trial, of guanfacine-ER compared to placebo for CUD. Participants will start on guanfacine-ER 1mg nightly for 1-week (week 1) and slowly increase by 1mg/per week to a max dose of 4mg or maximum dose as tolerated through week 4. Patients will be maintained on the medication through week 11. During week 11, they will begin a taper to discontinuation, decreasing the dose of guanfacine by 1mg every 4 days until stopped during the last week of the study (week 12). The primary purpose of this study is therefore to investigate the effect of guanfacine-ER on reductions in cannabis use and explore its effects on impulsivity and withdrawal through a hybrid in person and virtual trial of treatment-seeking individuals with CUD. In light of COVID-19 viral transmission mitigation policies, we will make use of the technological applications of virtual visits, remote administration of urine drug testing and medication, and ecological momentary assessments (EMA) in conjunction with once monthly in person visits to the clinic during weeks 1, 4, 8, 12. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05273567
Study type	Interventional
Source	New York State Psychiatric Institute
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	June 1, 2022
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03253926` - Effect of Lorcaserin on Cannabis Withdrawal and Self-administration	Phase 1/Phase 2
Completed	`NCT04060602` - Personalized Feedback Intervention to Reduce Risky Cannabis Use.	N/A
Completed	`NCT01212081` - Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Recruiting	`NCT04988490` - Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
Recruiting	`NCT05188404` - Aging and Marijuana: Benefits, Effects, and Risks
Completed	`NCT03662737` - VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
Not yet recruiting	`NCT05999383` - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration	Phase 2
Terminated	`NCT04436055` - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Active, not recruiting	`NCT04374773` - Effects of Pregnancy-associated Hormones on THC Metabolism in Women	Phase 4
Completed	`NCT04316741` - Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use	N/A
Recruiting	`NCT05396638` - Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder	N/A
Recruiting	`NCT05309226` - Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
Recruiting	`NCT03859089` - Cannabis for Opioid Substitution Trial
Recruiting	`NCT05849636` - Alerta Cannabis: Evaluation of Web-based Tailored Intervention	N/A
Enrolling by invitation	`NCT05521321` - Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit	N/A
Recruiting	`NCT05119244` - Environment and Lung Cancer	N/A
Recruiting	`NCT04841655` - Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
Terminated	`NCT04100590` - Eye Tracking as a Biomarker of Cannabis Effects	Phase 2
Completed	`NCT05167097` - Mindsets and the Effectiveness of a Brief Intervention - Replication	N/A
Recruiting	`NCT04114903` - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity